使害羞
发表于 2025-3-28 14:37:49
http://reply.papertrans.cn/17/1672/167124/167124_41.png
GUMP
发表于 2025-3-28 19:42:09
http://reply.papertrans.cn/17/1672/167124/167124_42.png
类型
发表于 2025-3-29 01:06:35
Acute Promyelocytic Leukemia20 years; cure rates above 95% are expected when . retinoic acid (ATRA) is given with arsenic trioxide (ATO) and low-dose anthracyclines. The presenting features of pediatric APL may include severe bleeding and thrombotic complications, which contribute to the high early death rate. The incidence of
CHAR
发表于 2025-3-29 05:01:12
Myeloid Proliferation Associated with Down Syndrome (ML-DS, TAM) This myeloproliferative disorder is caused by a mutation in the hematopoietic transcription factor GATA1, which is strongly associated with Down syndrome. Despite spontaneous remission without therapy within the first 3 months in most patients, serious complications occur in 5–10% of patients resul
名词
发表于 2025-3-29 08:02:59
http://reply.papertrans.cn/17/1672/167124/167124_45.png
蚀刻
发表于 2025-3-29 12:35:14
http://reply.papertrans.cn/17/1672/167124/167124_46.png
etidronate
发表于 2025-3-29 18:26:37
Advanced MDS in Childrens with 2–19% or bone marrow blasts with 5–19% are classified as advanced MDS. Aging-related somatic variants acquired in the hematopoietic cells are associated with the pathogenesis of adult MDS, whereas pediatric MDS often occurs in the context of germline predispositions. Besides well-known inheri
头脑冷静
发表于 2025-3-29 20:51:24
http://reply.papertrans.cn/17/1672/167124/167124_48.png
混沌
发表于 2025-3-30 03:02:16
Stem Cell Transplantation and Cellular Immunotherapies for Pediatric AMLin patients with high-risk acute myeloid leukemia (AML). Although transplant-related mortality occurs in ~5% of patients, HSCT is still considered the only available curative option for most patients with high-risk AML. Many factors such as the stem cell donor source, conditioning regimen, and time
Basal-Ganglia
发表于 2025-3-30 07:34:53
Pediatric AML in Resource-Limited Countriesreas in low- and middle-income countries (LMICs), survival rates are merely 10–40%. Reasons for these differences are the lack of early recognition and referral, the lack of diagnostic and treatment response monitoring capacities, the lack of resources for adequate anticancer treatment, the lack of